There are 2949 resources available
FGFR inhibitors
Presenter: Yohann Loriot
Session: New drugs in development: What will be approved in 2025?
Resources:
Slides
Webcast
Antibody Drug Conjugate (ADC)
Presenter: Victor Moreno Garcia
Session: New drugs in development: What will be approved in 2025?
Resources:
Slides
Webcast
Epigenetic drugs: EZH2, BET and LDSD1
Presenter: Sophie Postel-Vinay
Session: New drugs in development: What will be approved in 2025?
Resources:
Slides
Webcast
Future strategies of using radiotherapy as an immune-stimulating agent
Presenter: Fernanda Herrera
Session: New drugs in development: What will be approved in 2025?
Resources:
Slides
Webcast
cfDNA in CNS tumours
Presenter: Joan Seoane
Session: Liquid biopsy: Beyond targeted panel sequencing in cancer research and therapy
Resources:
Slides
Webcast
Cell-free DNA methylomes and early-stage cancers
Presenter: Daniel De Carvalho
Session: Liquid biopsy: Beyond targeted panel sequencing in cancer research and therapy
Resources:
Slides
Webcast
The clinical perspective: Trials fit for purpose in 2020 and beyond
Presenter: Irene Braña
Session: Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics
Resources:
Slides
Webcast
The regulatory perspective: How to look for certainty in terra incognita
Presenter: Francesco Pignatti
Session: Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics
Resources:
Slides
Webcast
The HTA perspective: Is tissue-independent approval the next top model?
Presenter: Sonia Garcia Perez
Session: Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics
Resources:
Slides
Webcast
Implementation of NGS diagnostics in the NHS: The example of Belgium
Presenter: Marc Van Den Bulcke
Session: Reshaping the model of evidence generation in the era of molecularly driven tissue-independent therapeutics
Resources:
Slides
Webcast